Spectral Medical Inc. (TSX: EDT)

Market Cap	140.01M
Revenue (ttm)	2.01M
Net Income (ttm)	-25.03M
Shares Out	282.84M
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Open	0.495
Previous Close	0.485
Day's Range	0.495 - 0.495
52-Week Range	0.385 - 0.750
Beta	0.97
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 27, 2025

About Spectral Medical

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrat...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1991
• Employees: 29
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: EDT

Financial Performance

In 2023, Spectral Medical's revenue was 1.60 million, a decrease of -4.14% compared to the previous year's 1.67 million. Losses were -15.66 million, 38.8% more than in 2022.